|
Jun 12
|
GENOMMA LAB INTERNATIONAL INFORMS TOTAL PREPAYMENT OF "LAB 23" UNSECURED LOCAL BOND (CEBUR)
|
|
Feb 10
|
Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter 2024 Earnings Results Conference Call
|
|
Oct 4
|
Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2024 Earnings Results Conference Call
|
|
Oct 2
|
GENOMMA LAB PHARMA MANUFACTURING FACILITY GRANTED PENDING GMP CERTIFICATION FOR THE MEXICAN MARKET
|
|
Jul 25
|
Genomma Lab Announces Strategic Bolt-On Acquisition of Four Brands
|
|
Jul 24
|
Genomma Lab Internacional Announces Results for the Second Quarter 2024
|
|
Jun 13
|
GENOMMA LAB INTERNACIONAL ANNOUNCES EIGHTH DIVIDEND PAYMENT
|
|
May 8
|
Marzam's New Strategy Will Focus on Strengthening the Company's Position within Pharmaceutical Sector
|
|
May 6
|
Agreement Signed for Share Redemption in Marzam
|
|
Feb 22
|
Genomma Lab Internacional Reports Fourth Quarter & Full Year 2023 Results
|
|
Nov 30
|
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America
|
|
Aug 8
|
GENOMMA LAB INTERNACIONAL INFORMS THE VOLUNTARILY PREPAYMENT OF THE SECOND TRANCHE OF ITS IFC SECURED LOAN
|
|
Aug 7
|
GENOMMA LAB MANUFACTURING FACILITY GRANTED COFEPRIS OPERATING LICENSE FOR ALL ITS PHARMA / OTC MANUFACTURING LINES
|
|
Jul 5
|
Genomma Lab Announces Second Quarter 2023 Financial Results Call and Webcast
|